

CITATION REPORT

List of articles citing

Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials

DOI: 10.1007/s13300-020-00889-9
Diabetes Therapy, 2020, 11, 1925-1934.

Source: <https://exaly.com/paper-pdf/75844868/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|----|--|-----|-----------|
| 14 | Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?. <i>Diabetes Therapy</i> , 2020 , 11, 2207-2219 | 3.6 | 21 |
| 13 | A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 1621-1630 | 3.4 | 3 |
| 12 | Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension. <i>Vascular Pharmacology</i> , 2021 , 138, 106839 | 5.9 | 2 |
| 11 | Surprises in cardiology: efficacy of gliflozines in heart failure even in the absence of diabetes. <i>European Heart Journal Supplements</i> , 2021 , 23, E40-E44 | 1.5 | 3 |
| 10 | [Update on diastolic heart failure].. <i>Der Internist</i> , 2022 , 1 | 0 | 0 |
| 9 | New Diabetic Medication Sodium-Glucose Cotransporter-2 Inhibitors Can Induce Euglycemic Ketoacidosis and Mimic Surgical Diseases: A Case Report and Review of Literature.. <i>Frontiers in Surgery</i> , 2022 , 9, 828649 | 2.3 | 0 |
| 8 | Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. <i>Terapevticheskii Arkhiv</i> , 2021 , 93, 1491-1497 | 0.9 | 1 |
| 7 | Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial. <i>Russian Journal of Cardiology</i> , 2022 , 27, 4945 | 1.3 | 0 |
| 6 | Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives. 2022 , 25, 275-287 | | |
| 5 | Sodium-Glucose Cotransporter Inhibitors as Antidiabetic Drugs: Current Development and Future Perspectives. 2022 , 65, 10848-10881 | | 0 |
| 4 | Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. 2022 , 11, 4660 | | 0 |
| 3 | Sodium alginate-based drug delivery for diabetes management: A review. 2023 , 236, 123986 | | 0 |
| 2 | CLINICAL EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE. 2023 , 76, 645-650 | | 0 |
| 1 | Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders. 14, | | 0 |